Get the Stockscreener App
38.48
1.08%
-0.42
Pre-market:
38.23
-0.25
-0.65%
Veracyte Inc stock is traded at $38.48, with a volume of 944.82K.
It is down -1.08% in the last 24 hours and up +13.04% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$38.90
Open:
$38.17
24h Volume:
944.82K
Relative Volume:
1.00
Market Cap:
$3.07B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
35.43
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
-4.80%
1M Performance:
+13.04%
6M Performance:
-2.21%
1Y Performance:
+35.06%
1-Day Range:
$37.72
$39.57
1-Week Range:
$37.66
$40.97
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
38.48 | 3.10B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte stock (US92347M1009): earnings momentum and cancer diagnostics focus - AD HOC NEWS
Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test - Moomoo
Veracyte (VCYT) Gains CMS Coverage for TrueMRD Monitoring Test - GuruFocus
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test - Contract Pharma
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TipRanks
Veracyte’s bladder cancer test receives Medicare coverage - Investing.com
Veracyte secures Medicare coverage for Truemrd monitoring test in muscle-invasive bladder cancer - marketscreener.com
Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer - TradingView
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - New Castle News
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings - simplywall.st
Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are - Yahoo Finance
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors - GuruFocus
Artisan Partners (NYSE: VCYT) reports 5.50M shares, 6.9% stake in Veracyte - Stock Titan
Morgan Stanley Initiates Veracyte(VCYT.US) With Sell Rating, Announces Target Price $39.7 - Moomoo
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte - Stock Titan
State of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Stapley Marc - Moomoo
Why Veracyte Stock Is Skyrocketing Higher This Week - AOL.com
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies - simplywall.st
Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23%News and Statistics - IndexBox
Veracyte, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-05-08 - Seeking Alpha
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte SVP McGuire sells $398,211 in shares By Investing.com - Investing.com South Africa
Veracyte SVP McGuire sells $398,211 in shares - Investing.com India
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan - Stock Titan
Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Number of shareholders of Veracyte, Inc. – MUN:12V - TradingView
Veracyte price target raised to $42 from $40 at Canaccord - TipRanks
Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives - Sahm
VCYT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
The Nasdaq Biotechnology Index closed up more than 2.1%. Among its constituents, Pyxis Oncology rose 25.68%, Veracyte gained 25.08%, MannKind (MNKD) increased 24.83%, Replimune was up 19.16%, and Novavax (NVAX) rose 15.56%. - Bitget
Veracyte (VCYT) Jumps As Strong Q1 Fuels Bullish Guidance - timothysykes.com
Ann McGuire sells 6,658 shares under 10b5-1 plan (VCYT) - Stock Titan
Veracyte Surges 21.1% Amid Sector-Wide Rally - AlphaStreet
UBS Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Veracyte, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Key Risks, and Results Overview - Minichart
VCYT Stock Jumps As Raised Guidance Fuels Bullish Momentum - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
FMR LLC (NASDAQ: VCYT) discloses 9.7% holding — 7.7M shares - Stock Titan
UBS Adjusts Price Target on Veracyte to $52 From $48, Maintains Buy Rating - marketscreener.com
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $42 to $48 - Moomoo
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript - Insider Monkey
Veracyte, Inc. 1Q 2026: Revenue $139.07M, EPS $0.35— 10-Q Summary - TradingView
Veracyte (NASDAQ: VCYT) Q1 profit surges as revenue climbs 21% - Stock Titan
Veracyte Q1 2026 slides: EPS beats by 57%, guidance raised - Investing.com Australia
Veracyte Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Revenue Guidance; Shares Up Pre-Bell - marketscreener.com
Veracyte: Raising FY26 Testing Rev Guidance to $570M to $580M >VCYT - Moomoo
Veracyte Announces First Quarter 2026 Financial Results - BioSpace
Veracyte Q1 Earnings Call Highlights - Yahoo Finance
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):